Reports Q1 revenue $106.5M, consensus $115.86M. “In Q1, we continued to advance both our global pipeline and commercial business,” said CEO Samantha Du. “We are rapidly expanding our global portfolio, having recently presented promising data for two next-generation oncology therapies at AACR, and we look forward to presenting updated results for ZL-1310 at the 2025 ASCO Annual Meeting. We remain on track to initiate a pivotal study for ZL-1310 in SCLC this year, with the goal of securing FDA approval in 2027. In parallel, we are also exploring opportunities in first-line SCLC and other neuroendocrine tumors to unlock the full potential of this important global asset. On the commercial front, we continued to expand patient access for key products and are leveraging our existing infrastructure to support upcoming launches and our next wave of blockbuster opportunities. With a strong foundation in place, we are well positioned to drive growth and profitability, and to further our mission of becoming a leading global biopharmaceutical company.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Zai Lab: Strong Pipeline and Strategic Partnerships Drive Buy Rating Despite Revenue Adjustments
- Zai Lab presents data from studies evaluating two oncology therapies
- Zai Lab: Hold Rating Amid Growth Potential and Competitive Pressures
- Zai Lab announces China NMPA acceptance of repotrectinib sNDA
- Zai Lab’s Resilience and Promising Pipeline Justify Buy Rating Amid Geopolitical Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue